387570 — Finemedix Co Income Statement
0.000.00%
- KR₩44bn
- KR₩38bn
- KR₩10bn
Annual income statement for Finemedix Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 7,254 | 8,142 | 10,154 | 9,960 |
Cost of Revenue | ||||
Gross Profit | 3,443 | 4,406 | 5,640 | 5,705 |
Selling / General / Administrative Expenses | ||||
Depreciation and Amortization | ||||
Unusual Expense / Income | ||||
Total Operating Expenses | 9,559 | 9,003 | 9,281 | 9,990 |
Operating Profit | -2,306 | -861 | 874 | -29.2 |
Gain / Loss on Sale of Assets | ||||
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -2,200 | 294 | 1,178 | -206 |
Provision for Income Taxes | ||||
Net Income After Taxes | -1,543 | 240 | 1,176 | -24.2 |
Minority Interest | ||||
Net Income Before Extraordinary Items | ||||
Net Income | -1,410 | 240 | 1,176 | -24.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -1,410 | 240 | 1,176 | -24.2 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -275 | 182 | 326 | 99.9 |
Dividends per Share |